Skip to main content
SpringerLink
Log in

New drug development for pediatric oncology

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lukens JN: Progress resulting from clinical trials. Cancer 74:2710–2718, 1994.

    Google Scholar 

  2. Pratt CB: The conduct of phase I–II clinical trials in children with cancer. Med Ped Oncol 19:304–309, 1991.

    Google Scholar 

  3. Leventhal BG, Graham ML: Clinical trials in pediatric oncology. Sem Oncol 15:482–487, 1988.

    Google Scholar 

  4. Ungerleider RS, Marsoni S: Phase I and II trials in pediatric cancer patients: a rational. In: Poplack DG, Massimo L, Cornaglia-Ferraris P (eds) The Role of Pharmacology in Pediatric Oncology. Boston: Kluwer Academic, 1987, pp 159–170.

    Google Scholar 

  5. Furman WL, Pratt CB, Rivera GK, Krischer JP, Kamen BK, Vietti TJ: Mortality in pediatric phase I clinical trials. J Natl Cancer Inst 81:1193–1194, 1989.

    Google Scholar 

  6. Estey EE, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105–1115, 1986.

    Google Scholar 

  7. Von Hoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–122, 1991.

    Google Scholar 

  8. Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC: Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 70:865–869, 1986.

    Google Scholar 

  9. Gaynon PS, Ettinger LJ, Moel D, Siegel SE, Baum ES, Krivit W, Hammond GD: Pediatric phase I trial of carboplatin: A Childrens Cancer Study Group report. Cancer Treat Rep 71:1039–1042, 1987.

    Google Scholar 

  10. Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, Glaubiger DL, Cohen LF: Phase I trial of mitoxantrone in children. Cancer Treat Rep 69:403–407, 1985.

    Google Scholar 

  11. Pappo AS, Vats T, Williams TE, Bernstein M, Kamen BA: Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 21:280–282, 1993.

    Google Scholar 

  12. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH, Pratt CB: Phase I trial of taxol in children with refractory solid tumors: A Ped iatric Oncology Group Study. J Clin Oncol 11:2324–2329, 1993.

    Google Scholar 

  13. Bernstein ML, Whitehead VM, Grier H, Dubowy R, Land V, Devine S, Murphy S, Kung F: A phase I trial of fazarabine in refractory pediatric solid tumors. Invest New Drugs 11:309–312, 1993.

    Google Scholar 

  14. Mathew P, Ribeiro RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, Bowman L, Meyer W, Avery L, Crist W: Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 12:1452–1457, 1994.

    Google Scholar 

  15. Adamson PC, Balis FM, Miser J, Arndt C, Wells RJ, Gillespie A, Aronson L, Penta JS, Clendeninn NJ, Poplack DG: Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 52:521–524, 1992.

    Google Scholar 

  16. Pratt CB, Meyer WH, Douglass EC, Bowman L, Wilimas J, Ochs J, Marina N, Avery L, Thompson EI: A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer 71:3661–3665, 1993.

    Google Scholar 

  17. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539–543, 1994.

    Google Scholar 

  18. Glaubiger DL, Von Hoff DD, Holcenberg JS, Kamen BA, Pratt C, Ungerleider RS: The relative tolerance of children and adults to anticancer drugs. Front Radiat Ther Oncol 16:42–49, 1982.

    Google Scholar 

  19. Marsoni S, Ungerleider RS, Hurso SB, Simon RM, Hammershaimb LD: Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 69:1263–1269, 1985.

    Google Scholar 

  20. Finklestein JZ, Higgins G, Krivit W, Hammond D: Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep 63:1331–1333, 1979.

    Google Scholar 

  21. Lokich JJ, Chawla PL, Jaffe N, Frei E: Phase I evaluation of cyclocytidine (NSC 145668). Cancer Chemother Rep 59:389–393, 1975.

    Google Scholar 

  22. Burgess MA, Bodey GP, Minow RA, Gottlieb JA: Phase I–II evaluation of cyclocytidine. Cancer Treat Rep 61:437–443, 1977.

    Google Scholar 

  23. Higgins GR, Shore NA, Etcubanas E, Momparler RL, Jamin D, Rucker N: Dianhydrogalactitol: Phase I clinical pharmacological studies in childhood cancer. Proc Am Assoc Cancer Res 165:658, 1976.

    Google Scholar 

  24. Eagan RT, Moertel CG, Hahn RG, Schutt AJ: Brief communication: phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC 132313). J Natl Cancer Inst 56:179–181, 1976.

    Google Scholar 

  25. Miser JS, Miser AW, Smithson WA, Coccia PF, Ames MM, Davis DM, Hughs CD, Gilchrist GS: A phase I trial of indicine N-oxide in childhood malignancy. Proc Am Soc Clin Oncol 1:137, 1982.

    Google Scholar 

  26. Kovach JS, Ames MM, Powis G, Moertel CG, Hahn RG, Creagan ET: Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res 39:4540–4544, 1979.

    Google Scholar 

  27. Rivera G, Pratt CB: Phase I study of 3-deazauridine (NSC 126849) in children with cancer. Clin Pharmacol Ther 25:244–245, 1979.

    Google Scholar 

  28. Creaven PJ, Priore RL, Mittelman A, Bruno S, Henderson ES, Rustum YM, Solomon JK: Phase I trial and pharmacokinetics of a daily × 5 schedule of 3-deazauridine. Cancer Treat Rep 66:81–84, 1982.

    Google Scholar 

  29. Pediatric Oncology Group, Operations Office: SWOG 7843.

  30. Benjamin RS, Keating MJ, Swenerton KD, Legha S, McCredie KB: Clinical studies with rubidazone. Cancer Treat Rep 63:925–929, 1979.

    Google Scholar 

  31. Sullivan MP, Nelson JA, Feldman S, Nguyen BV: Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer Chemother Pharmacol 21:78–84, 1988.

    Google Scholar 

  32. Sklaroff RB, Casper ES, Magill GB, Young CW: Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer Treat Rep 64:1247–1251, 1980.

    Google Scholar 

  33. Pediatric Oncology Group, Operations Office, POG 8155.

  34. Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP: Phase I study of L-alanosine using a daily × 3 schedule. Cancer Treat Rep 66:73–76, 1982.

    Google Scholar 

  35. Holcenberg JS, Tutsch KD, Earhart RH, Ungerleider RS, Kamen BA, Pratt CB, Gribble TJ, Glaubiger DL: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rep 70:703–709, 1986.

    Google Scholar 

  36. Von Hoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, Young RC: Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249–252, 1981.

    Google Scholar 

  37. Tan CTC, Hancock CH, Mondora A, Hoffrman NW: Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986). Cancer Res 44:831–835, 1984.

    Google Scholar 

  38. Ettinger LJ, Siegel SE, Belasco JB, Evans AE, Ruccione KS, Jamin DC, Rohrbaugh TM, Higgins GR: Phase I clinical evaluation of diaziquone in childhood cancer. Cancer Treat Rep 69:323–327, 1985.

    Google Scholar 

  39. Bedikian AY, Bodey GP, Burgess MA, Freireich EJ: Phase I study of aziridinylbenzoquinone (NSC 182986). Cancer Clin Trials 4:459–463, 1981.

    Google Scholar 

  40. Griffin JP, Newman RA, McCormack JJ, Krakoff IH: Clinical and clinical pharmacologic studies of aziridinyl-benzoquinone. Cancer Treat Rep 66:1321–1325, 1982.

    Google Scholar 

  41. CTEP Annual Report 1982.

  42. Ohnuma T, Sridhar KS, Ratner LH, Holland JF: Phase I study of indicine N-oxide in patients with advanced cancer. Cancer Treat Rep 66:1509–1515, 1982.

    Google Scholar 

  43. Taylor S, Belt R, Haas C, Stephens R, Hoogstraten B: Phase I studies of indicine N-oxide (IND) in two dose schedules. Proc Am Assoc Cancer Res 342:90, 1980.

    Google Scholar 

  44. Cook BA, Sinnhuber JR, Thomas PJ, Oison TA, Silverman TA, Jones R, Whitehead VM, Ruymann FB: Hepatic failure secondary to indicine N-oxide toxicity: A Pediatric Oncology Group Study. Cancer 52:61–63, 1983.

    Google Scholar 

  45. Priego V, Luc V, Bonnern E, Rahman A, Smith F, Schein P, Woolley P: A phase I study and pharmacology of diammine (1,1) cyclobutane dicarboxylato (2–1–0) platinum (CBDCA) administered on a weekly schedule. Proc Am Soc Clin Oncol 2:117, 1983.

    Google Scholar 

  46. CTEP Annual Report, 1988.

  47. Pratt CB, Sinkule JA, Etcubanas E, Douglass EC, Crom DB, Choi K, Avery L: Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors. Invest New Drugs 4:149–153, 1986.

    Google Scholar 

  48. Spiegel RJ, Blum RH, Levin M, Pinto CA, Wernz JC, Speyer JL, Hoffman KS, Muggia FM: Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Cancer Res 42:354–358, 1982.

    Google Scholar 

  49. Leyvraz S, Ohnuma T, Lassus M, Holland JF: Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hr infusion. J Clin Oncol 3:1385–1392, 1985.

    Google Scholar 

  50. Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC: Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 57:222–225, 1986.

    Google Scholar 

  51. Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner K, Cavalli F: A phase I trial of cisdiammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 2:297–304, 1984.

    Google Scholar 

  52. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147, 1982.

    Google Scholar 

  53. Balis FM, Lange BJ, Packer RJ, Holcenberg JS, Ettinger LJ, Sallan SE, Heideman RL, Zimm S, Smithson WA, Cogliano-Shutta NA, Reaman GH, Poplack DG: Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res 45:5169–5172, 1985.

    Google Scholar 

  54. Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham BA, Hartshorn JN, Newman RA, Haugh LD, Young JA: Trial of tiazofurin administered by IV bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71:141–149, 1987.

    Google Scholar 

  55. Maroun JA, Stewart DJ: Phase I study of tiazofurin (2-B-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Invest New Drugs 8:S33-S39, 1990.

    Google Scholar 

  56. Melink TJ, Von Hoff DD, Kuhn JG, Hersh MR, Sternson LA, Patton TF, Siegler R, Boldt DH, Clark GM: Phase I evaluation and pharmacokinetics of tiazofurin (2-B-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45:2859–2865, 1985.

    Google Scholar 

  57. Neidhart J, Metz E, Gochnour D, Dallaire B, Grillo-Lopez A, Malspeis L: Phase I study of tiazofurin (2-B-D-ribofuranosyl-4-thiazole-carboxamide, NSC 286193). Proc Am Soc Clin Oncol 3:36, 1984.

    Google Scholar 

  58. Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CAI: Phase I clinical investigation of 1,4-dihydroxy-5,8-bis{{{2-[(2-hydroxyethyl)amino]ethyl}amino}}-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980.

    Google Scholar 

  59. Von Hoff DD, Meyers JW, Kuhn J, Sandbach JF, Pocelinko R, Clark G, Coltman CA: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl) dihydrochloride (CL216, 942). Cancer Res 41:3118–3121, 1981.

    Google Scholar 

  60. Balis FM, Patel R, Luks E, Doherty KM, Holcenberg JS, Tan C, Reaman GH, Belasco J, Ettinger LJ, Zimm S, Poplack DG: Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 47:4973–4976, 1987.

    Google Scholar 

  61. Fanucchi MP, Walsh TD, Fleisher M, Lokos G, Williams L, Cassidy C, Vidal P, Chou TC, Niedzwiecki D, Young CW: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47:3303–3308, 1987.

    Google Scholar 

  62. Huan SD, Legha SS, Raber MN, Krakoff IH: Phase I studies of trimetrexate using single and weekly dose schedules. Invest New Drugs 9:199–206, 1991.

    Google Scholar 

  63. Heideman RL, Kelley JA, Packer RJ, Reaman GH, Roth JS, Ettinger LJ, Doherty KM, Jeffries SL, Poplack DG: A pediatric phase I and pharmacokinetic study of spirohydantoin mustard. Cancer Res 48:2292–2295, 1988.

    Google Scholar 

  64. Brown TD, Ettinger DS, Donehower R: A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. J Clin Oncol 4:1270–1276, 1986.

    Google Scholar 

  65. Heideman RL, Gillespie A, Ford H, Reaman GH, Balis FM, Tan C, Sato J, Ettinger LJ, Packer RJ, Poplack DG: Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res 49:5213–5216, 1989.

    Google Scholar 

  66. Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G: Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. Cancer Res 51:1105–1108, 1991.

    Google Scholar 

  67. Pratt CB, Relling MV, Meyer WH, Douglass EC, Kellie SJ, Avery L: Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors. Am J Clin Oncol 14:483–486, 1991.

    Google Scholar 

  68. CTEP Annual Report, 1991.

  69. Stewart JA, McCormack JJ, Tong W, Low JB, Roberts JD, Blow A, Whitfield LR, Haugh LD, Grove WR, Grillo Lopez AJ, DeLap RJ: Phase I clinical and pharmacokinetic study of trimetrexate using a daily × 5 schedule. Cancer Res 48:5029–5035, 1988.

    Google Scholar 

  70. Grochow LB, Noe DA, Dole GB, Rowinsky EK, Ettinger DS, Graham ML, McGuire WP, Donehower RC: Phase I trial of trimetrexate glucoronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 81:124–130, 1989.

    Google Scholar 

  71. Adamson PC, Balis FM, Miser J, Wells RJ, Bleyer WA, Williams TE, Gillespie A, Penta JA, Clendeninn NJ, Poplack DG: Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res 50:4464–4467, 1990.

    Google Scholar 

  72. Brenckman W, Lazlo J, Morgan E, Williams T, Guaspari A, Sigel C, Blum R: Phase I evaluation of BW 301U administered orally on five consecutive days. Proc Am Soc Clin Oncol 4:45, 1985.

    Google Scholar 

  73. Laszlo J, Brenckman WD, Morgan E, Clendeninn NJ, Williams T, Currie V, Young C: Initial clinical studies of piritrexim. Natl Cancer Inst Monogr 5:121–125, 1987.

    Google Scholar 

  74. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG: Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 53:1032–1036, 1993.

    Google Scholar 

  75. Reid JM, Burch PA, Benson LM, Gilbert JA, Richardson RL, Ames MM: Phase I clinical and pharmacologic evaluation of topotecan administered by a 24-hour continuous infusion. Proc Am Assoc Cancer Res 33:1553, 1992.

    Google Scholar 

  76. Abbruzzese JL, Madden T, Schmidt S, Eaton G, Raber MN: Phase I trial of topotecan (TT) administered by 24-hour infusion without and with G-CSF. Proc Am Assoc Cancer Res 34:329, 1993.

    Google Scholar 

  77. ten Bokkel Huinink WW, Rodenhuis S, Beijnen J, Dubbelman R, Koier I: Phase I study of the topoisomerase I inhibitor topotecan (SK&F 104864-A). Proc Am Soc Clin Oncol 11:110, 1992.

    Google Scholar 

  78. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Von Hoff D, Garteiz D, Raber M: A phase I trial of topotecan (TOPO) administered by a 24-hour infusion. Proc Am Assoc Cancer Res 32:206, 1991.

    Google Scholar 

  79. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: tresponses observed in metastaticmelanoma. J Clin Oncol 5:1232–1239, 1987.

    Google Scholar 

  80. Horikoshi N, Ogawa M, Inoue K, Aiba K, Mukaiyama T, Ogihara A, Sumida T, Akatsuka Y, Bessho A, Funakoshi S, Inamoto Y, Koga H: Pharmacokinetics of a 24-hour infusion of taxol. Proc Am Soc Clin Oncol 12:146, 1993.

    Google Scholar 

  81. Tamura T, Sasaki Y, Shinkai T, Eguchi K, Ohe Y, Nishio M, Kunikane H, Arioka H, Karato A, Omatsu H, Nakashima H, Shiraishi J, Saijo N: Phase I and pharmacokinetic study of taxol by a 24-hour intravenous infusion. Proc Am Soc Clin Oncol 12:143, 1993.

    Google Scholar 

  82. Seibel N, Ames M, Ivy P, Krailo M, Reid J, Kent P, Reaman G: Phase I and pharmacologic study of paclitaxel in refractory pediatric leukemia: A Children's Cancer Group study. Proc Am Soc Clin Oncol 13:1068, 1994.

    Google Scholar 

  83. Weitman SD, Relling MV, Hurwitz CA: Taxol — The pediatric experience. In: McGuire W, Rowinsky E (eds) Taxol in Cancer Treatment. New York: Marcel Dekker Inc., 1995, pp 307–319.

    Google Scholar 

  84. Tubergen D, Pratt C, Stewart C, Vietti T: Phase I study of topotecan in children with refractory solid tumors: A Pediatric Oncology Group study. Proc Am Soc Clin Oncol 13:167, 1994.

    Google Scholar 

  85. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647–656, 1992.

    Google Scholar 

  86. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony stimulating factor. J Natl Cancer Inst 85:1499–1507, 1993.

    Google Scholar 

  87. Verweij J, Lund B, Beijnen J, Planting A, de Boer Dennert M, Koier I, Rosing H, Hansen H: Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673–678, 1993.

    Google Scholar 

  88. Blaney S, Seibel N, O'Brien M, Mosher R, Reaman G, Poplack D, Balis F: A phase I study of taxotere in pediatric patients. Proc Am Assoc Cancer Res 35:211, 1994.

    Google Scholar 

  89. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M: Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037–1042, 1993.

    Google Scholar 

  90. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, LeBail N, Von Hoff DD: Phase I clinical trial of taxotere adminstered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950–958, 1993.

    Google Scholar 

  91. Houghton P, Horton J, Houghton J: Drug sensitivity and resistance in the xenograft model. In: Mauer H, Ruymann F, Pochedly C (eds) Rhabdomyosarcoma and Related Tumors in Children and Adolescents. Boca Raton: CRC Press, 1991, pp 107–203.

    Google Scholar 

  92. Faries D: Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4:147–164, 1994.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, Hematology and Immunology, The University of Texas Health Science Center and the Institute for Drug Development, 78284-7810, San Antonio, Texas, USA

    Steven Weitman

  2. Department of Pediatric Oncology, The University of Texas Southwestern Medical Center, 75235, Dallas, Texas, USA

    Lisa Carlson

  3. St. Jude Children's Hospital and Department of Pediatrics, University of Tennessee, 38101-0318, Memphis, Tennessee, USA

    Charles B. Pratt

Authors
  1. Steven Weitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles B. Pratt
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Steven Weitman, Department of Pediatrics, 7703 Floyd Curl Drive, University of Texas Health Science Center, San Antonio, TX 782-84-7810, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weitman, S., Carlson, L. & Pratt, C.B. New drug development for pediatric oncology. Invest New Drugs 14, 1–10 (1996). https://doi.org/10.1007/BF00173677

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173677

Keywords

Search

Navigation